Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Daily News

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

Todd Neale

November 29, 2016

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

July 17, 2014

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Warfarin Offers Poor Protection Against Radial Occlusion After Transradial Angiography

November 26, 2013

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Industry News

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

November 06, 2011

Advertisement

Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Warfarin Offers Poor Protection Against Radial Occlusion After Transradial Angiography

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content